Amgen Inc. (AMGN) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 55
- Profitability 60
- Business Quality 80
- Balance Sheet 55
- Cash Flow 80
Why this rating?
Health 68/100 — High Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Amgen Inc. (AMGN) is a Drug Manufacturers - General company in the Healthcare sector. Compound Radar rates Amgen Inc. 68/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Moderate
- Balance Sheet Adequate
- Valuation Fair
Financial highlights
Valuation
- P/E 27.82
- Forward P/E 18.29
- PEG 2.65
- EV/Revenue 7.49
Profitability
- Revenue Growth 9.5%
- Gross Margin 71.9%
- Operating Margin 35.5%
- Net Margin 23.0%
- ROE 91.5%
Financial strength
- Cash $13.99B
- Debt $57.30B
- Net Cash $-43.31B
- Free Cash Flow $8.10B
- Current Ratio 1.37
Similar companies
Peers in Drug Manufacturers - General, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Eli Lilly and Company Drug Manufacturers - General LLY$1,281.91 86 Health 86 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- AstraZeneca PLC Drug Manufacturers - General AZN$170.08 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Gilead Sciences, Inc. Drug Manufacturers - General GILD$159.08 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Biogen Inc. Drug Manufacturers - General BIIB$252.73 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- AbbVie Inc. Drug Manufacturers - General ABBV$286.39 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Bristol-Myers Squibb Company Drug Manufacturers - General BMY$61.55 72 Health 72 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Pfizer Inc. Drug Manufacturers - General PFE$29.80 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Johnson & Johnson Drug Manufacturers - General JNJ$268.73 69 Health 69 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
FAQ
How Compound Radar scores and tracks Amgen Inc. (AMGN).